Matinas BioPharma Reports $5.2 Million Net Loss in Q2 2025, Seeks Additional Funding

Matinas BioPharma Holdings, Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $5.2 million, a slight decrease from the $5.7 million loss recorded in the same period of 2024. For the six months ending June 30, 2025, the company reported a net loss of $6.9 million, down from $11.5 million in the prior year. The reduction in losses is attributed to a significant decrease in research and development expenses, which fell to $0 for the quarter and $85,000 for the six months, compared to $3.4 million and $6.8 million, respectively, in 2024. General and administrative expenses also decreased to $1.8 million for the quarter and $3.7 million for the six months, down from $2.5 million and $4.9 million in the prior year.

The company’s total assets decreased to $11.4 million as of June 30, 2025, from $12.6 million at the end of 2024. Current assets also saw a decline, primarily due to a reduction in cash and cash equivalents, which stood at $6.5 million compared to $7.3 million at the end of the previous fiscal year. Current liabilities decreased significantly to $1.8 million from $2.7 million, largely due to a reduction in accrued expenses. The company’s stockholders’ equity increased slightly to $7.7 million, reflecting the issuance of 3,300 shares of Series C Convertible Preferred Stock in a private placement that generated $3.3 million in gross proceeds.

Operationally, Matinas BioPharma has paused its development program for MAT2203, which has led to a reduction in associated costs. The company is currently focused on securing partnerships to advance MAT2203 into Phase 3 clinical trials and is exploring options for monetizing its assets. The company’s employee headcount has also been reduced, contributing to lower operational costs. As of June 30, 2025, the company had 5,086,985 shares of common stock outstanding, with no new shares issued under its At-The-Market Sales Agreement during the reporting period.

Looking ahead, Matinas BioPharma anticipates continued operating losses as it seeks to secure additional funding to support its clinical development efforts. The company has expressed concerns regarding its liquidity, stating that its current cash reserves may not be sufficient to fund operations beyond the next twelve months. The company plans to explore various financing options, including public or private equity offerings and collaborations, to ensure its ongoing operations and development initiatives. The management has indicated that while they believe in the viability of their strategy, there is substantial doubt about the company's ability to continue as a going concern without securing additional financing.